Please login to the form below

Not currently logged in
Email:
Password:

People, October, 2011

Recent high-profile moves in the pharmaceutical and healthcare industries
Mover of the month is Jean-Pierre Garnier who has been appointed as chairman of the board of directors at Actelion

Mover of the month

  
 Jean-Pierre Garnier

Swiss biopharma company Actelion has made Jean-Pierre Garnier chairman of its board of directors. Robert Cawthorn, who has been chairman since the inception of the company, will stay on the board until the 2012 annual general meeting. From 2001 to 2008, Garnier was the first CEO of GlaxoSmithKline, assuming the role on the merger of SmithKline Beecham and Glaxo Wellcome. He joined SmithKline Beecham in 1990 as president of its pharmaceutical business in North America and served as chairman, pharmaceuticals from 1994 until his appointment as COO in 1995. He was elected to the company's board in 1992. He became CEO of SmithKline Beecham in April 2000. Prior to SmithKline Beecham, Garnier was president of Schering-Plough's US business. From 2008 to 2010, he was CEO of Pierre Fabre Labs. Garnier holds a PhD in pharmacology and an MSc in pharmaceutical science from the University Louis Pasteur of Strasbourg in France. 


 

Spain-based Almirall has appointed Alfredo Barón as area director for Southern and Eastern Europe to head commercial operations there. He joined Almirall in 2000 as product manager in marketing and has been head of marketing, director of sales and commercial director, managing the product portfolio in the cardiovascular, urology and diabetes fields.

 

Alfredo Barón



Ornella Barra  

For the second consecutive year Ornella Barra, chief executive of Alliance Boots' pharmaceutical wholesale division, has been ranked in the top 10 of global leaders outside the US of Fortune magazine's '50 most powerful international women in business'. Barra is a pharmacist and founded the European Pharmacists' Forum over ten years ago to support pharmacists in the delivery of healthcare.

Dr Trevor Mundel, current global head of development for Novartis, has been named president of The Bill & Melinda Gates Foundation Global Health Programme. In this position, he will oversee the foundation's global health grant portfolio, which, to date, includes more than $14.7bn in grants and lead efforts to develop and deliver drugs, vaccines and other tools to fight developing-world diseases including HIV/AIDS, tuberculosis and malaria as well as eradicating polio. Since 2003, Mundel has been a senior executive and scientist at Novartis, most recently as global head of development. He starts at the foundation on December 1.



 Trevor Mundel



Tilly Beazeley

Premier Research Group has appointed Tilly Beazeley as senior director, business development, covering the UK and Scandinavia. She has 15 years of sales and operations experience in international pharmaceutical development, healthcare services, educational services and paediatric health.


Bronwen Kaye, former senior director of government relations for Pfizer, has joined APCO as a senior advisor to the company's healthcare practice. She has more than 25 years of executive-level experience in government relations for the healthcare sector, having led numerous legislative advancements in immunisation, biotechnology, medical research and other areas of medicine. Prior to her role at Pfizer, she was senior director of government relations for Wyeth (now part of Pfizer). She was also director of government relations for Lederle Laboratories, the pharmaceutical division of American Cyanamid.


Bronwen Kaye

 

 


Pat Pearson

Former Red Consultancy health MD Pat Pearson has joined ex-colleague Paul Davies to set up a new healthcare offering at firstlight, based in the UK. Pearson and Davies will split the MD role. Davies launched the agency in 2009, having been head of corporate communications at Red. Pearson described the agency as a 'breakaway' rather than a 'start-up'. Pearson is a former deputy MD at Ruder Finn and media adviser at the Department of Health. 

The MSI Consultancy has appointed Cassandra Rix as head of market access. She has been with MSI since April, when the firm merged with red kite consulting group, where she worked in the market access division from 2005. Prior to this she spent a decade in the pharmaceutical industry.

Cassandra Rix

UCB has elected Gerhard Mayr as chairman of the board from May 2012, when Karel Boone's term ends at the age of 70. Mayr, a member of the board since 2005, is independent director and member of the remuneration and appointments committee. He is also member of the audit committee. Born in Austria, he holds a master's degree in chemical engineering from the Swiss Federal Institute of Technology and a master of business administration degree from Stanford University. In March 2004, he retired as executive vice president of pharmaceutical operations at Eli Lilly & Co after 32 years.

Dr Frank Morich has been named CEO of Nycomed, following the company's acquisition by Takeda on September 30, 2011. He takes this role in addition to his role as executive vice president, international operations (Americas/Europe), at Takeda Pharmaceuticals International, Inc.

AstraZeneca's chairman, Louis Schweitzer, is stepping down from the role, which he has held since 2005, according to a report from Sky News. 

Thomas Christély has been appointed as CEO of Silence. He was previously the company's COO and has been with the group for 10 years. Tony Sedgwick has been appointed as chief business officer. He is experienced in the life sciences arena and has a strong track record in licensing agreements in biotechnology. He will have the task of building a larger business development team.

Geron Corporation has appointed Dr John A Scarlett as its chief executive officer and to its board of directors. Dr Scarlett has over 25 years of executive leadership experience in the pharmaceutical and biotechnology industry. Most recently, he was president and CEO of Proteolix, which was acquired by Onyx Pharmaceuticals in November 2009. He was also a founder and CEO at Tercica, as well as Sensus Drug Development Corp. David Greenwood, interim CEO, president and CFO, remains as president and CFO until the end of 2011.

Non-profit international pharmaceutical supply chain organisation Rx-360 has elected nine new board members, who will serve for a three-year term until the end of 2014. They are: Janice Berman (Takeda), Heike Falkenhagen (Boehringer Ingelheim), Hubertus Folttmann (BASF), Jaspret Gill (Baxter), Brian Johnson (Pfizer), Patrica Latzo (Mylan), Elizabeth Pileggi (Teva), Swroop Sahota (Merck) and Melissa Seymour (Biogen Idec).


Related links

FAQ: How do I get my move listed

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Clarity of vision, insight and a thought-through strategic approach are our tools for delivering solutions that benefit our clients and...

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....